125 related articles for article (PubMed ID: 38884602)
1. The endothelin-1-driven tumor-stroma feed-forward loops in high-grade serous ovarian cancer.
Tocci P; Roman C; Sestito R; Caprara V; Sacconi A; Molineris I; Tonon G; Blandino G; Bagnato A
Clin Sci (Lond); 2024 Jun; ():. PubMed ID: 38884602
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition.
Tocci P; Roman C; Sestito R; Di Castro V; Sacconi A; Molineris I; Paolini F; Carosi M; Tonon G; Blandino G; Bagnato A
Cell Death Dis; 2023 Jan; 14(1):5. PubMed ID: 36604418
[TBL] [Abstract][Full Text] [Related]
3. Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer.
Sestito R; Tocci P; Roman C; Di Castro V; Bagnato A
J Exp Clin Cancer Res; 2022 Apr; 41(1):157. PubMed ID: 35477522
[TBL] [Abstract][Full Text] [Related]
4. β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer.
Tocci P; Cianfrocca R; Di Castro V; Rosanò L; Sacconi A; Donzelli S; Bonfiglio S; Bucci G; Vizza E; Ferrandina G; Scambia G; Tonon G; Blandino G; Bagnato A
Nat Commun; 2019 Jul; 10(1):3196. PubMed ID: 31324767
[TBL] [Abstract][Full Text] [Related]
5. Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer.
Chellini L; Caprara V; Spadaro F; Sestito R; Bagnato A; Rosanò L
Matrix Biol; 2019 Aug; 81():17-33. PubMed ID: 30367951
[TBL] [Abstract][Full Text] [Related]
6. hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.
Di Modugno F; Caprara V; Chellini L; Tocci P; Spadaro F; Ferrandina G; Sacconi A; Blandino G; Nisticò P; Bagnato A; Rosanò L
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):3132-3137. PubMed ID: 29439204
[TBL] [Abstract][Full Text] [Related]
7. YAP and endothelin-1 signaling: an emerging alliance in cancer.
Tocci P; Blandino G; Bagnato A
J Exp Clin Cancer Res; 2021 Jan; 40(1):27. PubMed ID: 33422090
[TBL] [Abstract][Full Text] [Related]
8. Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.
Cianfrocca R; Tocci P; Rosanò L; Caprara V; Sestito R; Di Castro V; Bagnato A
Oncotarget; 2016 Apr; 7(14):17790-804. PubMed ID: 26909598
[TBL] [Abstract][Full Text] [Related]
9. The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential.
Del Rio D; Masi I; Caprara V; Ottavi F; Albertini Petroni G; Salvati E; Trisciuoglio D; Giannitelli SM; Bagnato A; Mauri E; Spadaro F; Rosanò L
Cell Death Dis; 2024 May; 15(5):358. PubMed ID: 38777849
[TBL] [Abstract][Full Text] [Related]
10. The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer.
Masi I; Ottavi F; Del Rio D; Caprara V; Vastarelli C; Giannitelli SM; Fianco G; Mozetic P; Buttarelli M; Ferrandina G; Scambia G; Gallo D; Rainer A; Bagnato A; Spadaro F; Rosanò L
Cell Death Dis; 2023 Jan; 14(1):73. PubMed ID: 36717550
[TBL] [Abstract][Full Text] [Related]
11. Targeting Endothelin-1 Receptor/β-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach.
Tocci P; Rosanò L; Bagnato A
Front Endocrinol (Lausanne); 2019; 10():609. PubMed ID: 31551935
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma.
Russignan A; Dal Collo G; Bagnato A; Tamassia N; Bugatti M; Belleri M; Lorenzi L; Borsi E; Bazzoni R; Gottardi M; Terragna C; Vermi W; Giacomini A; Presta M; Cassatella MA; Krampera M; Tecchio C
Front Oncol; 2020; 10():600025. PubMed ID: 33489901
[TBL] [Abstract][Full Text] [Related]
13. The significance of the alteration of 8-OHdG in serous ovarian carcinoma.
Xu X; Wang Y; Guo W; Zhou Y; Lv C; Chen X; Liu K
J Ovarian Res; 2013 Oct; 6(1):74. PubMed ID: 24165045
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
15. Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin-1/β-arr1 Axis.
Del Rio D; Masi I; Caprara V; Spadaro F; Ottavi F; Strippoli R; Sandoval P; López-Cabrera M; Sainz de la Cuesta R; Bagnato A; Rosanò L
Front Cell Dev Biol; 2021; 9():764375. PubMed ID: 34926453
[TBL] [Abstract][Full Text] [Related]
16. Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.
Sestito R; Cianfrocca R; Rosanò L; Tocci P; Di Castro V; Caprara V; Bagnato A
Life Sci; 2016 Aug; 159():43-48. PubMed ID: 26776834
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
King ER; Zu Z; Tsang YT; Deavers MT; Malpica A; Mok SC; Gershenson DM; Wong KK
Gynecol Oncol; 2011 Oct; 123(1):13-8. PubMed ID: 21726895
[TBL] [Abstract][Full Text] [Related]
18. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R
Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964
[TBL] [Abstract][Full Text] [Related]
19. Targeting endothelin-1 receptor/β-arrestin1 network for the treatment of ovarian cancer.
Rosanò L; Cianfrocca R; Sestito R; Tocci P; Di Castro V; Bagnato A
Expert Opin Ther Targets; 2017 Oct; 21(10):925-932. PubMed ID: 28758529
[TBL] [Abstract][Full Text] [Related]
20. The endothelin receptor antagonist macitentan ameliorates endothelin-mediated vasoconstriction and promotes the survival of retinal ganglion cells in rats.
Kodati B; Zhang W; He S; Pham JH; Beall KJ; Swanger ZE; Krishnamoorthy VR; Harris PE; Hall T; Tran AV; Chaphalkar RM; Chavala SH; Stankowska DL; Krishnamoorthy RR
Front Ophthalmol (Lausanne); 2023; 3():. PubMed ID: 38464735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
